Navigation Links
Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Date:2/5/2008

g developed for the

treatment of acute agitation in patients with schizophrenia or bipolar

disorder. Alexza reported positive results from a 129 patient Phase 2a

clinical trial in 2007. In the second half of 2007, Alexza conducted

an End of Phase 2 meeting with the FDA and completed enrollment in a

multiple-dose tolerability and pharmacokinetics clinical trial in

schizophrenic patients. Alexza plans to initiate two AZ-004 Phase 3

clinical trials during 2008, with the first Phase 3 clinical trial

scheduled to start in late Q1 2008 and the second Phase 3 clinical

trial scheduled to start Q3 2008. AZ-004 is being developed through

Symphony Allegro, a product development partnership formed between

Alexza and Symphony Capital, LLC.

-- AZ-001 (Staccato prochlorperazine) is being developed for the acute

treatment of migraine headaches. Alexza reported positive results from

a 400 patient Phase 2b clinical trial in 2007. Alexza is conducting a

thorough QT clinical trial in subjects and a 28-day inhalation

toxicology study in animals. Dosing has been completed in both of

these studies and data analysis is expected to be completed by the end

of Q1 2008. These data, along with the data from three previously

completed clinical trials, represent testing in more than 500 patients

and subjects, and will serve as the basis for an End of Phase 2 meeting

with the FDA, projected for late Q2 2008.

-- AZ-104 (Staccato loxapine), a lower dose version of AZ-004, is being

developed for the acute treatment of migraine headaches. In December

2007, Alexza completed enrollment of a Phase 2a proof-of-concept

clinical trial with AZ-104 in patients with migraine headache. The

Phase 2a clinical trial was an in-clinic, multi-center, randomized,

double blind
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... CHICAGO, Nov. 10 Advanced Life Sciences Holdings, ... engaged in the discovery, development and commercialization of novel ... respiratory diseases, today announced its financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ) , The net loss ...
... NEW YORK, Nov. 10 Reportlinker.com announces ... available in its catalogue. , The ... Market Outlook , http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... drug delivery industry has in recent years ...
Cached Medicine Technology:Advanced Life Sciences Announces Third Quarter 2009 Financial Results 2Advanced Life Sciences Announces Third Quarter 2009 Financial Results 3Advanced Life Sciences Announces Third Quarter 2009 Financial Results 4Advanced Life Sciences Announces Third Quarter 2009 Financial Results 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6Advanced Life Sciences Announces Third Quarter 2009 Financial Results 7Advanced Life Sciences Announces Third Quarter 2009 Financial Results 8Advanced Life Sciences Announces Third Quarter 2009 Financial Results 9Advanced Life Sciences Announces Third Quarter 2009 Financial Results 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 2Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 3Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 4Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 5Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 6Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 7Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 8Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 9Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 11
(Date:8/3/2015)... ... 03, 2015 , ... From 2006-2017 the number of dental ... market research compiled for the National Association of Dental Laboratories ( NADL ) ... of Labor Statistics. As the number of dental laboratories decreases, dentists will have ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
(Date:8/3/2015)... ... ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing doctor for ... suffering and using medications with strong side effects. This had already forced him to ... or wait longer hours in the waiting rooms. Instead, he went home at the ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Foot ... of a new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region ... ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is ...
(Date:8/3/2015)... ... August 03, 2015 , ... The American Institute ... an agreement to collaborate across a wide range of initiatives ranging from code ... among architects. , “Our combined membership, consisting of practicing design professionals, code officials, ...
Breaking Medicine News(10 mins):Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3
... 6 Mergent, Inc., administrator for the,Healthshares(TM) Indexes, ... Exchange Traded Funds, today announced the following,changes with ... May 9, 2008:,Masimo Corporation (Nasdaq: MASI ) ... in the HealthShares(TM) Composite Index, Quest,Diagnostics Inc (NYSE: ...
... Traffic Reached Record Levels of 51.9 Million Unique Monthly Users and ... ... Health Corp. (Nasdaq:,WBMD) today announced financial results for the three months ... quarter, as,WebMD continued to consolidate its position as the leading source ...
... the annual shareholders,meeting of Sigma-Aldrich Corporation (Nasdaq: SIAL ... re-elected: David R. Harvey, W. Lee,McCollum, Jai P. Nagarkatti, ... R. G. Sear, D. Dean Spatz and Barrett A. ... of Medtronic, Inc., was,elected to her first term as ...
... deals another blow to homocysteine theory , , TUESDAY, May ... supplements aimed at reducing blood levels of the amino ... and stroke, a long-term study found. , It,s the ... lowering homocysteine levels could reduce the incidence of cardiovascular ...
... Healthcare Workers Demonstrate to Protect Their Voice & Vote ... The battle,over the direction of the Service Employees International ... of hearings was held to,determine the fate of more ... Workers -- West (UHW). UHW represents 150,000,caregivers in hospitals, ...
... Epitomics, Inc. announced,today that its Hangzhou subsidiary has ... of its novel line of rabbit monoclonal,antibodies. "This ... quality management and ultimately the finest quality,antibodies available ... Yu,President and CEO of Epitomics, Inc., "ISO ...
Cached Medicine News:Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes 2Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes 3Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes 4Health News:WebMD Announces First Quarter Financial Results 2Health News:WebMD Announces First Quarter Financial Results 3Health News:WebMD Announces First Quarter Financial Results 4Health News:WebMD Announces First Quarter Financial Results 5Health News:WebMD Announces First Quarter Financial Results 6Health News:WebMD Announces First Quarter Financial Results 7Health News:WebMD Announces First Quarter Financial Results 8Health News:WebMD Announces First Quarter Financial Results 9Health News:WebMD Announces First Quarter Financial Results 10Health News:WebMD Announces First Quarter Financial Results 11Health News:WebMD Announces First Quarter Financial Results 12Health News:WebMD Announces First Quarter Financial Results 13Health News:WebMD Announces First Quarter Financial Results 14Health News:WebMD Announces First Quarter Financial Results 15Health News:WebMD Announces First Quarter Financial Results 16Health News:WebMD Announces First Quarter Financial Results 17Health News:WebMD Announces First Quarter Financial Results 18Health News:WebMD Announces First Quarter Financial Results 19Health News:WebMD Announces First Quarter Financial Results 20Health News:Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend 2Health News:Folic Acid Doesn't Help the Heart 2Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies. 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: